TwinStrand Biosciences Announces Second U.S. Patent Trial and Appeal Board Decision Upholding All Claims of TwinStrand’s ‘127 Patent
The PTAB again rejected Guardant Health's challenge to TwinStrand's '127 patent, upholding all 30 challenged claims on remand from the Federal Circuit under a new legal framework. Guardant had already been found to willfully infringe this patent and the '631 patent in a November 2023 jury verdict, with final judgment entered in August 2026 awarding more than $245.2 million in damages, royalties and interest.
Key figures
- Damages awarded
- $245.2 million
- Patents at issue
- ["U.S. Patent No. 10,760,127","U.S. Patent No. 10,287,631"]
- Royalty end date
- March 2033
- Ongoing royalty rate
- 6%
- Challenged claims rejected
- 30
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.